AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 4.58 |
Market Cap | 271.75M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.27 |
PE Ratio (ttm) | -3.69 |
Forward PE | n/a |
Analyst | Buy |
Ask | 4.94 |
Volume | 388,601 |
Avg. Volume (20D) | 403,501 |
Open | 4.83 |
Previous Close | 4.75 |
Day's Range | 4.69 - 4.98 |
52-Week Range | 0.90 - 6.19 |
Beta | undefined |
About RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrei...
Analyst Forecast
According to 8 analyst ratings, the average rating for RZLT stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 145.20% from the latest price.
1 month ago · seekingalpha.com
Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism MarketRezolute, Inc. expects to report top-line results from the phase 3 sunRIZE study using ersodetug + placebo to treat patients with Congenital Hyperinsulinism in the 2nd half of 2025. The global Congeni...